Clinical outcomes of Angio Jet pharmacomechanical thrombectomy versus catheter-directed thrombolysis for the treatment of filter-related caval thrombosis

BACKGROUND The inferior vena cava filter is utilized worldwide to intercept thrombi and to reduce the risk of fatal pulmonary embolism(PE).However,filter-related thrombosis is a complication of filter implantation.Endovascular methods such as AngioJet rheolytic thrombectomy(ART)and catheter-directed thrombolysis(CDT)can treat filter-related caval thrombosis,but the clinical outcomes of both treatment modalities have not been determined.AIM To compare the treatment outcomes of AngioJet rheolytic thrombectomy vs catheter-directed thrombolysis in patients with filter-related caval thrombosis.METHODS In this single-center retrospective study,65 patients(34 males and 31 females;mean age:59.0±13.43 years)with intrafilter and inferior vena cava thrombosis were enrolled between January 2021 and August 2022.These patients were assigned to either the AngioJet group(n=44)or the CDT group(n=21).Clinical data and imaging information were collected.Evaluation measures included thrombus clearance rate,periprocedural complications,urokinase dosage,incidence of PE,limb circumference difference,length of stay,and filter removal rate.RESULTS Technical success rates were 100%in the AngioJet and CDT groups.In the AngioJet group,grade II and grade III thrombus clearance was achieved in 26(59.09%)and 14(31.82%)patients,respectively.In the CDT group,grade II and grade III thrombus clearance was accomplished in 11(52.38%)patients and 8(38.10%)patients,respectively(P>0.05).The peridiameter difference of the thigh was significantly reduced in patients from both groups after treatment(P<0.05).The median dosage of urokinase was 0.08(0.02,0.25)million U in the AngioJet group and 1.50(1.17,1.83)million U in the CDT group(P<0.05).Minor bleeding was shown in 4(19.05%)patients in the CDT group,and when it was compared with that in the AngioJet group,the difference was statistically significant(P<0.05).No major bleeding occurred.Seven(15.91%)patients in the AngioJet group had hemoglobinuria and 1(4.76%)patient in the CDT group had bacteremia.There were 8(18.18%)patients with PE in the AngioJet group and 4(19.05%)patients in the CDT group before the intervention(P>0.05).Computed tomography angiopulmonography(CTA)showed that PE was resolved after the intervention.New PE occurred in 4(9.09%)patients in the AngioJet group and in 2(9.52%)patients in the CDT group after theintervention(P>0.05).These cases of PE were asymptomatic.The mean length of stay was longer in the CDT group(11.67±5.34 d)than in the AngioJet group(10.64±3.52 d)(P<0.05).The filter was successfully retrieved in the first phase in 10(47.62%)patients in the CDT group and in 15(34.09%)patients in the AngioJet group(P>0.05).Cumulative removal was accomplished in 17(80.95%)out of 21 patients in the CDT group and in 42(95.45%)out of 44 patients in the ART group(P>0.05).The median indwelling time for patients with successful retrieval was 16(13139)d in the CDT group and 59(12231)d in the ART group(P>0.05).CONCLUSION Compared with catheter-directed thrombolysis,AngioJet rheolytic thrombectomy can achieve similar thrombus clearance effects,improve the filter retrieval rate,reduce the urokinase dosage and lower the risk of bleeding events in patients with filter-related caval thrombosis.

Transhepatic catheter-directed thrombolysis for portal vein thrombosis after partial splenic embolization in combination with balloon-occluded retrograde transvenous obliteration of splenorenal shunt

A 66-year-old woman underwent partial splenic embolization （PSE） for hypersplenisrn with idiopathic portal hypertension （IPH）. One week later, contrast-enhanced CT revealed extensive portal vein thrombosis （PVT） and dilated portosystemic shunts. The PVT was not dissolved by the intravenous administration of urokinase. The right portal vein was canulated via the percutaneous transhepatic route under ultrasonic guidance and a 4 Fr. straight catheter was advanced into the portal vein through the thrombus. Transhepatic catheter-directed thrombolysis was performed to dissolve the PVT and a splenorenal shunt was concurrently occluded to increase portal blood flow, using balloon-occluded retrograde transvenous obliteration （BRTO） technique. Subsequent contrast-enhanced CT showed good patency of the portal vein and thrombosed splenorenal shunt. Transhepatic catheter-directed thrombolysis combined with BRTO is feasible and effective for PVT with portosystemic shunts.

Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis

AIM To evaluate the safety and efficacy of agitation thrombolysis(AT) combined with catheter-directed thrombolysis(CDT) for the treatment of non-cirrhotic acute portal vein thrombosis(PVT). METHODS Nine patients with non-cirrhotic acute PVT who underwent AT combined with CDT were analyzed retrospectively. Portography was carried out via the transjugular intrahepatic portosystemic(commonly known as TIP) or percutaneous transhepatic(commonly known as PT) route, followed by AT combined with CDT. Complications of the procedure, and the changes in clinical symptoms, hemodynamics of the portal vein and liver function were recorded. Follow-up was scheduled at1, 3 and 6 mo after treatment, and every 6 mo thereafter, or when the patients developed clinical symptoms related to PVT. Color Doppler ultrasound and contrast-enhanced computed tomography/magnetic resonance imaging were performed during the follow-up period to determine the condition of the portal vein.RESULTS AT combined with CDT was successfully performed. The portal vein was reached via the TIP route in 6 patients, and via the PT route in 3 patients. All clinical symptoms were relieved or disappeared, with the exception of 1 patient who died of intestinal necrosis 9 d after treatment. Significant differences in the changes in portal vein hemodynamics were observed, including the maximum lumen occupancy of PVT, portal vein pressure and flow velocity between pre-and posttreatment(P < 0.05). During the follow-up period, recurrence was observed in 1 patient at 19 mo after the procedure, and the portal vein was patent in the remaining patients.CONCLUSION AT combined with CDT is a safe and effective method for the treatment of non-cirrhotic acute PVT.

Clinical Efficacy of Neurointerventional Catheter Thrombolysis for Cerebral Infarction

Objective.To analyze the clinical efficacy of neurointerventional catheter thrombolysis for cerebral infarction.Methods.A total of 56 patients with cerebral infarction admitted to our hospital from April 2018 to June 2019 were enrolled for the experimental study.Two different treatments were applied to patients,and patients were divided into observation groups and controls according to different treatment methods.After grouped into two groups the control group was treated with intravenous thrombolysis.The observation group was treated with neurointerventional arterial catheter thrombolysis.The treatment effect,NIHSS score and BI index,neurological deficit score before and after treatment,and coagulation index were compared between the two groups.Results.The therapeutic effect of the observation group(92.86%)was significantly different from that of the control group(67.86%),and the observation group was higher than the control group.The data of the observation group in the NIHSS score and the BI index were 5.42±1.77 and 95.64±2.15,respectively,which were better than the control group.The neurological deficit scores of the observation group before and after treatment were 19.88±6.24 and 9.14±5.81,respectively.After treatment,the difference was significant compared with the control group,P<0.05.The coagulation indexes of the observation group in FIB,PT,TT,etc.were respectively 3.68±1.04,11.46±1.62,15.37±2.46,all were better than the control group(2.13±0.47,13.72±2.72,19.85±2.62),P<0.05.Conclusion.the clinical efficacy of neurointerventional arterial catheter thrombolysis for cerebral infarction is significant,it can effectively promote the recovery of various functional conditions of patients with cerebral infarction,which is worthy of further application and promotion.

A randomized trail comparing primary percutaneous coronary intervention with a strategy of short-acting thrombolysis and immediate planned primary percutaneous coronary intervention in acute myocardial infarction

Objective This study was to evaluate the efficacy and safety of a short acting reduced dose fibrinolytic regimen to promote early infarct related artery (IRA) patency for acyute myocardial infarction (AMI) patients referred for percutaneous coronary intervention (PCI).Methods Following aspirin and heparin, 166 patients were randomized to a 50 mg bolus of recombinant tissue type plasminogen activator(rt PA) or to a same volume sodium chloride injection followed by immediate primary PCI. The end points included patency rates on catheterization laboratory (cath lab) arrival, revascularization results when PCI was performed, complication rates, left ventricular function and restored patency rate following PCI. Results Patency on cath lab arrival was 64% with rt PA (34% TIMI 3,30% TIMI 2), while 31% of placebo (13% TIMI 3, 18% TIMI 2). There was no difference in the restored TIMI 3 rates of IRA between the two groups (85% vs 87%). No difference were observed in stroke or major bleeding. Left ventricular function was similar in both groups (52±9% vs 50±8%), but left ventricular ejection fraction fraction (LVEF) was higher with patent IRA (TIMI 3) on cath lab arrival than that of others (56±12% vs 48±10%).Conclusions Strategy thrombolytic regimens were compatible with subsequent PCI lead to more frequenc early recanalization (before cath lab arrival), which facilitates greater left ventricular function preservation with no augmentation of adverse events.

Interventional treatment for symptomatic acute-subacute portal and superior mesenteric vein thrombosis

AIM: To summarize our methods and experience with interventional treatment for symptomatic acute-sub-acute portal vein and superior mesenteric vein throm-bosis (PV-SMV) thrombosis. METHODS: Forty-six patients (30 males, 16 females, aged 17-68 years) with symptomatic acute-subacute portal and superior mesenteric vein thrombosis were ac-curately diagnosed with Doppler ultrasound scans, com-puted tomography and magnetic resonance imaging. They were treated with interventional therapy, including direct thrombolysis (26 cases through a transjugular intrahepatic portosystemic shunt; 6 through percutane-ous transhepatic portal vein cannulation) and indirect thrombolysis (10 through the femoral artery to superior mesenteric artery catheterization; 4 through the radial artery to superior mesenteric artery catheterization). RESULTS: The blood reperfusion of PV-SMV was achieved completely or partially in 34 patients 3-13 d after thrombolysis. In 11 patients there was no PV-SMV blood reperfusion but the number of collateral vessels increased signif icantly. Symptoms in these 45 patients were improved dramatically without severe operationalcomplications. In 1 patient, the thrombi did not respond to the interventional treatment and resulted in intestinal necrosis, which required surgical treatment. In 3 patients with interventional treatment, thrombi reformed 1, 3 and 4 mo after treatment. In these 3 patients, indirect PV-SMV thrombolysis was performed again and was successful. CONCLUSION: Interventional treatment, including direct or indirect PV-SMV thrombolysis, is a safe and effective method for patients with symptomatic acutesubacute PV-SMV thrombosis.

Diagnostic neuroradiology:Ready for the neurointerventional age?

Acute cerebral ischemia or stroke is currently considered an emergency for which therapeutic options are available if the therapeutic window of 4.5 h is respected.Imaging modalities have progressed greatly over the last few decades,rendering ischemia detectable in the first hours after the event.However,in order for treatment to be efficacious it is necessary to speed up all the processes before the start of therapy.Thus,one must decrease the time to arrival at the hospital and to the radiological method that is to be employed(be it computed tomography or magnetic resonance imaging);only then will the medical or interventional techniques available fulfill their potential.

Interventional neuroradiology of stroke, still not dead

Since the National Institute of Neurological Disorders and Stroke trial,intravenous thrombolysis has been gaining wide acceptance as the modality of treatment for acute embolic stroke,with a current therapeutic window of up to 4.5 h.Both imaging[with either magnetic resonance imaging(MRI)or computed tomography(CT)]and interventional techniques(thrombolysis and/or thrombectomy)have since improved and provided us with additional imaging of the penumbra using CT or MRI and more advanced thrombolysis or thrombectomy strategies that have been embraced in many centers dealing with patients with acute cerebral ischemia.These techniques,however,have come under scrutiny due to their accrued healthcare costs and have been questioned following major recent studies.These studies basically showed that interventional techniques were not superior to the traditional intravenous thrombolysis techniques and that penumbra imaging could not determine what patients would benefit from more aggressive(i.e.,interventional)treatment.We discuss this in the light of the latest developments in both diagnostic and interventional neuroradiology and point out why further studies are needed in order to define the right choices for patients with acute stroke.Indeed,these studies were in part conducted with suboptimal patient recruitment strategies and did not always use the latest interventional techniques available today.So,while these studies may have raised some relevant questions,at the same time,definitive answers have not been given,in our opinion.

PCI in Post Thrombolysis Stable STEMI Patients: A Timeline in Question

ST elevation myocardial infarction (STEMI) occupies a significant portion of the cardiovascular disease spectrum and poses a continuing challenge on the health care delivery system worldwide. A dilemma exists in the clinical triage system for appropriate strategic modalities of treatment, based on underlying triad of patient-hospital-cardiac pathological factors as well as cut off timelines. Current European Society of Cardiology (ESC) guideline recommends percutaneous coronary intervention (PCI) within 3 to 24 hours in post thrombolysis stable patients. This review critically evaluated the evidences underlying the ESC recommendation. Trials included in this review are SIAM III, GRACIA 1, CAPITAL-AMI, CARESS-IN-AMI, NORDISTEMI, PRAGUE-1, WEST and LEIPZIG. Most of the evidences support the notion for immediate post thrombolysis PCI in stable patients within 1.9 to 2.7 hours, which contradicts the ESC timeline of up to 24 hours. Also, there is a reduced generalizability of the trial results due to differences in the design of the various trials, study population, composite endpoints, variations in drug dose & formulation, co-administration of pharmacotherapies and type of stents used. This warrants further research for standardization & optimization of the treatment protocol with respect to post thrombolysis PCI in stable STEMI patients.

Progress in interventional radiology treatment of pulmonary embolism:A brief review

Pulmonary embolism represents a common life-threatening condition.Prompt identification and treatment of this pathological condition are mandatory.In cases of massive pulmonary embolism and hemodynamic instability or right heart failure,interventional radiology treatment for pulmonary embolism is emerging as an alternative to medical treatment(systemic thrombolysis)and surgical treatment.Interventional radiology techniques include percutaneous endovascular catheter directed therapies as selective thrombolysis and thrombus aspiration,which can prove useful in cases of failure or infeasibility of medical and surgical approaches.

Comparison of the curative effect of intracoronary retrograde thrombolysis and thrombus aspiration combined with stent implantation on STEMI patients

Objective:To evaluate the short-term and long-term curative effects of precise intracoronary retrograde thrombolysis combined with stent implantation,thrombus aspiration combined with stent implantation,and traditional stent implantation in patients with acute ST-segment elevation myocardial infarction.Methods:From January 2018 to October 2019,184 patients diagnosed with acute ST-segment elevation myocardial infarction and infarction-related arterial blood flow TIMI 0 grade in the First Affiliated Hospital of Hainan Medical College and percutaneous coronary intervention(PCI)were selected.According to different surgical methods,patients were divided into intracoronary retrograde thrombolysis combined with stent implantation group(thrombolysis group,n=57 cases),thrombus aspiration combined with stent implantation group(aspiration group,n=57 cases)),traditional stent implantation group(traditional group,n=70 cases).Compare the incidence of no-reflow phenomenon after percutaneous coronary intervention,the rate of 1 hour ST_segment fall≥50%in the ECG after PCI,and the main adverse cardiovascular events(MACE)during hospitalization;compare the left ventricular end-diastolic diameter(LVEDD)、left ventricular ejection fraction(LVEF)and major adverse cardiovascular events at 1 year after PCI.Results:1.The short-term effects:The incidence of no-reflow phenomenon in the thrombolytic group was lower than that of the aspiration group and the traditional group,and the rate of 1hSTR≥50%was higher than that of the aspiration group and the traditional group,the difference was statistically significant(P<0.05).2.The long-term effects:1 year after percutaneous coronary intervention,the LVEDD of the thrombolytic group was lower than that of the aspiration group and the traditional group,while the LVEF was higher than the aspiration group and the traditional group,and the incidence of major adverse cardiovascular events in the thrombolytic group at was lowest,both the difference was statistically significant(P<0.05).Conclusion:The application of intracoronary retrograde thrombolysis combined with stent implantation in STEMI patients can reduce the occurrence of no-reflow,improve long-term cardiac function,and reduce the occurrence of major adverse cardiovascular events for short-term and long-term.

小球囊预扩张治疗布加综合征合并混合性下腔静脉血栓一期和分期治疗方案的疗效和成本效益对比

目的:对比分析小球囊预扩张治疗布加综合征(BCS)合并混合性下腔静脉血栓(IVCT)一期和分期治疗方案的疗效和成本效益。方法:回顾性收集2011年1月至2020年12月郑州大学第一附属医院收治的BCS合并混合性IVCT、行小球囊预扩张治疗的患者116例,其中,一期治疗方案49例,分期治疗方案67例。对比分析两种治疗方案的血栓溶解率、技术成功率、住院时间、住院费用、医保补偿率。结果:两种治疗方案中位总住院时间(22.0 d vs 22.5 d,P=0.303)和医保补偿率(58.92%vs 55.75%,P=0.965)差异无统计学意义,而一期治疗方案血栓溶解率(100.0%vs 87.5%,P=0.012)、技术成功率(100.0%vs 62.7%,P=0.001)和中位人均住院费用(45676.51元vs 61283.21元,P<0.001)均优于分期治疗方案。结论:一期治疗方案具有更高的溶栓效率和技术成功率,以及更低的住院费用,应被临床优先选择。

急性脑梗死介入治疗联合静脉溶栓治疗的效果观察

目的 探究介入治疗联合静脉溶栓对急性脑梗死患者的治疗效果。方法 80例急性脑梗死患者,合理且随机划分为对照组和观察组,每组40例。对照组采取静脉溶栓治疗,观察组在对照组基础上采用介入治疗。比较两组患者神经功能缺损评分、血清学相关指标(神经生长因子、神经元特异性烯醇化酶、脑钠肽)、活化部分凝血活酶时间、凝血酶原时间、凝血酶时间、纤维蛋白原、并发症发生情况。结果 观察组患者治疗后1 d、7 d、2周神经功能缺损评分均低于对照组(P<0.05)。治疗后,两组患者神经生长因子、神经元特异性烯醇化酶、脑钠肽水平均下降,且观察组患者神经生长因子(95.31±9.65)ng/ml、神经元特异性烯醇化酶(10.26±1.37)μg/L、脑钠肽(157.43±13.25)ng/L均低于对照组的(116.38±10.46)ng/ml、(15.86±1.86)μg/L、(189.46±17.78)ng/L(P<0.05)。治疗后,观察组患者活化部分凝血活酶时间(35.43±2.21)s、凝血酶原时间(13.26±1.53)s、凝血酶时间(17.46±2.24)s比对照组的(30.48±2.15)、(10.93±1.29)、(15.55±1.87)s更长,纤维蛋白原(2.44±0.43)g/L比对照组的(4.21±0.64)g/L更低(P<0.05)。观察组并发症发生率5.00%比对照组的25.00%更低(P<0.05)。结论 针对急性脑梗死患者,采取静脉溶栓联合介入治疗可有效改善患者神经功能及血清学状况,且可以有效改善活化部分凝血活酶时间等相关临床指标,减少相关并发症的发生,该治疗方案临床应用效果理想,预后效果良好,值得在临床广泛推广。

介入溶栓治疗颅内大血管狭窄急性闭塞致脑梗死的疗效及对患者血清BDNF GAP-43和NGF的影响

目的 探讨介入溶栓治疗颅内大血管狭窄急性闭塞致脑梗死的临床疗效及对患者血清脑源性神经营养因子(BDNF)、神经生长相关蛋白43(GAP-43)和神经生长因子(NGF)水平的影响。方法 将56例颅内大血管狭窄急性闭塞致脑梗死患者按治疗方法分为对照组(28例)和研究组(28例)。对照组患者给予常规治疗,研究组患者在对照组基础上给予介入溶栓治疗。比较两组临床疗效以及不良事件发生率,比较治疗前后两组患者美国国立卫生研究院卒中量表(NHISS)评分、脑血流灌注指标、生存质量综合评定问卷简表(WHOQOL-BREF)评分及血清BDNF、GAP-43和NGF水平。结果 治疗后两组患者NHISS评分均较治疗前降低,且研究组低于对照组(P<0.01);治疗后两组患者脑血流量(CBF)、脑血容量(CBV)、脑血流平均通过时间(MTT)均较治疗前升高,且研究组高于对照组(P<0.01)。治疗后,研究组患者WHOQDL-BREF各维度评分均高于对照组(P<0.01)。治疗后,两组患者血清BDNF、GAP-43和NGF水平均较治疗前升高,且研究组高于对照组(P<0.01)。研究组患者临床总有效率高于对照组(P<0.05),两组患者不良事件发生率比较差异无统计学意义(P>0.05)。结论 介入溶栓治疗颅内大血管狭窄急性闭塞致脑梗死能够显著改善患者神经缺损程度,改善脑部供血,提高其生活质量,疗效显著。

接受再灌注治疗的ST段抬高型心肌梗死患者死亡率性别差异的荟萃分析

目的 探讨接受再灌注治疗的ST段抬高型心肌梗死(STEMI)患者死亡率的性别差异。方法 全面检索PubMed、EMBASE、万方数据库、中国知网和谷歌学术等数据库自建库至2023年8月1日的文献中,对接受溶栓治疗或直接经皮冠状动脉介入术(PPCI)的STEMI患者短期或长期死亡率的性别差异进行对比的相关研究。观察性研究和随机对照研究均纳入本研究。使用Rev Man 5软件进行统计学分析。使用危险度(RR)和95%CI表示性别差异对STEMI患者死亡率的影响。使用漏斗图评估研究偏倚。结果 共纳入36项研究,其中33项观察性研究和3项随机对照研究,共108 132例STEMI患者,其中男性82 848例,女性25 284例。与男性患者相比,女性患者住院期间(RR=1.73,95%CI:1.52~1.98,P<0.001,I~2=69%)、1个月(RR=1.89,95%CI:1.74~2.06,P<0.001,I~2=46%)、1年(RR=1.56,95%CI:1.40~1.74,P<0.001,I~2=0%)和2年(RR=1.78,95%CI:1.51~2.10,P<0.001,I~2=43%)死亡率显著增加。在调整后的分析中,女性STEMI患者住院期间(RR=1.60,95%CI:1.27~2.02,P<0.001,I~2=69%)、1个月(RR=1.40,95%CI:1.04~1.88,P<0.001,I~2=65%)和2年(RR=1.25,95%CI:1.10~1.42,P<0.001,I~2=48%)死亡率仍明显高于男性患者。结论 对于接受再灌注治疗的STEMI患者,女性的短期和长期死亡率均高于男性。

针对性干预对阿替普酶溶栓治疗急性缺血性脑卒中后认知功能的影响

目的探讨针对性干预对阿替普酶溶栓治疗急性缺血性脑卒中后认知功能的影响。方法收集2020年1月至2023年6月亳州市人民医院收治的92例急性缺血性脑卒中患者的临床资料,根据住院期间是否接受了针对性干预将患者分为观察组(n=48)和对照组(n=44)。所有患者均成功接受了阿替普酶静脉溶栓治疗。比较两组患者的急性缺血性脑卒中病情、治疗情况、治疗前后认知功能及住院期间并发症发生情况。结果两组患者发病至溶栓的时间、卒中部位、美国国立卫生研究院卒中量表(NIHSS)评分、缺血灶最大直径及阿替普酶总剂量比较,差异均无统计学意义(P﹥0.05)。治疗后,两组患者蒙特利尔认知功能评估(MoCA)量表中各维度评分均高于本组治疗前,且观察组患者MoCA量表中各维度评分均高于对照组患者,差异均有统计学意义(P﹤0.05)。两组患者住院期间并发症的发生率比较,差异无统计学意义(P﹥0.05)。结论针对性干预可以进一步改善阿替普酶溶栓治疗急性缺血性脑卒中后患者的认知功能,并具有较好的安全性,值得临床推广。

急性脑梗死患者急诊介入溶栓治疗后早期神经功能恶化影响因素分析

目的:探讨急性脑梗死患者急诊介入溶栓治疗早期神经功能恶化(END)影响因素。方法:选择我院于2020年3月至2023年3月行急诊介入溶栓治疗的急性脑梗死患者105例,按照溶栓内24h是否发生END,分为END组34例与非END组71例。采用单因素分析影响END的相关因素;多因素Logistic回归分析影响END独立危险因素。结果:经单因素分析计数资料显示,END组和非END组性别、年龄、BMI、吸烟史、饮酒史、高血压史、糖尿病史、冠心病史和责任大血管分布差异无统计学意义(P>0.05);END组和非END组责任大血管狭窄程度比较差异具有统计学意义(P<0.05)。经单因素分析计量资料显示,END组与非END组入院时NIHSS评分、溶栓时间、白细胞计数、中性粒细胞计数、Lp-PLA2水平和脂蛋白a水平比较差异具有统计学意义(P<0.05);而END组与非END组发病至溶栓时间、D-二聚体和Hcy水平比较差异无统计学意义(P>0.05)。多因素Logistic回归分析的结果显示,责任大血管狭窄程度、入院时NIHSS评分、溶栓时间、白细胞计数、中性粒细胞计数、Lp-PLA2和脂蛋白a为影响END独立危险因素。结论:急性脑梗死患者急诊介入溶栓治疗后END发生率较高,且受多因素影响,其中责任大血管狭窄程度、入院时NIHSS评分、溶栓时间、白细胞计数、中性粒细胞计数、Lp-PLA2和脂蛋白a为影响END独立危险因素。

基于时间节点的院内快速急救干预模式用于脑梗死患者急诊静脉溶栓中的效果

目的探讨基于时间节点的院内快速急救干预模式对脑梗死患者急诊静脉溶栓的影响。方法选取本院80例2022年1月—2022年12月急诊静脉溶栓的脑梗死患者,分组方式为随机抽签法,各40例,对照组采用常规急救护理,观察组采用基于时间节点的院内快速急救干预模式,比较两组的护理效果。结果观察组CT检查完成时间、溶栓前等待时间较对照组短,60 min溶栓率较对照组高(均P<0.05);护理后,观察组神经功能缺损情况评分较对照组低、认知功能评分较对照组高(均P<0.05);护理后,观察组的上、下肢运动功能评分均较对照组高(均P<0.05);护理后,观察组日常生活能力评分、生活质量评分均较对照组高(均P<0.05)。结论基于时间节点的院内快速急救干预模式可缩短脑梗死患者急诊静脉溶栓前等待时间,改善患者的认知功能与运动功能,减轻神经功能损伤,提升日常生活能力与生活质量。

置管溶栓联合多种腔内介入术治疗下肢动脉硬化闭塞症的效果

目的:探究置管溶栓联合多种腔内介入术治疗下肢动脉硬化闭塞症的效果。方法:回顾性选取2015年5月—2023年5月三明市第二医院收治的90例下肢动脉硬化闭塞症患者。根据治疗方法的不同将其分为参照组和试验组,各45例。参照组给予多种腔内介入术治疗,试验组给予置管溶栓联合多种腔内介入术治疗。比较两组治疗前、治疗后1个月相关指标、足背动脉血流动力学、神经传导速度、疼痛程度及围手术期指标、手术疗效。结果:治疗后1个月,两组踝肱指数、足趾血氧饱和度及足部皮温、血管内径及血流量、下肢感觉及运动神经传导速度均升高,视觉模拟评分法(VAS)评分、血流峰速降低,差异有统计学意义(P<0.05)。两组踝肱指数、足趾血氧饱和度及足部皮温、血管内径、血流峰速及血流量、下肢感觉、运动神经传导速度及VAS评分比较,差异无统计学意义(P>0.05)。试验组手术时间与住院时间均短于参照组,差异有统计学意义(P<0.05)。试验组血管开通率高于参照组,支架植入率及截肢率均低于参照组,差异有统计学意义(P<0.05)。结论:下肢动脉硬化闭塞症采用置管溶栓联合多种腔内介入术可有效提高患者下肢神经传导速度,优化足背动脉血流动力学,同时能减少支架植入,降低截肢风险,缩短康复周期,其整体疗效更显著。

Efficacy of percutaneous mechanical thrombus removal in acute lower extremity deep venous thrombosis

BACKGROUND Acute lower extremity deep venous thrombosis(LEDVT)is a common vascular emergency with significant morbidity risks,including post-thrombotic syndrome(PTS)and pulmonary embolism.Traditional treatments like catheter-directed thrombolysis(CDT)often result in variable success rates and complications.AIM To investigate the therapeutic efficacy of percutaneous mechanical thrombus removal in acute LEDVT.METHODS A retrospective analysis was performed to examine 58 hospitalised patients with acute LEDVT between August 2019 and August 2022.The patients were categorised into the percutaneous mechanical thrombectomy(PMT)group(n=24)and CDT group(n=32).The follow-up,safety and treatment outcomes were compared between the two groups.The main observational indexes were venous patency score,thrombus removal effect,complications,hospitalisation duration and PTS.RESULTS The venous patency score was 9.04±1.40 in the PMT group and 8.81±1.60 in the CDT group,and the thrombus clearance rate was 100%in both groups.The complication rate was 8.33%in the PMT group and 34.84%in the CDT group,and the difference was statistically significant(P<0.05).The average hospitalisation duration was 6.54±2.48 days in the PMT group and 8.14±3.56 days in the CDT group.The incidence of PTS was lower in the PMT group than in the CDT group;however,the difference was not statistically significant(P<0.05).CONCLUSION Compared with CDT,treatment of LEDVT via PMT was associated with a better thrombus clearance rate,clinical therapeutic effect and PTS prevention function,but the difference was not statistically significant.Moreover,PMT was associated with a reduced urokinase dosage,shortened hospitalisation duration and reduced incidence of complications,such as infections and small haemorrhages.These results indicate that PMT has substantial beneficial effects in the treatment of LEDVT.